PSMA-Targeted Therapy Market Set to Expand by 2034 on Strong Pipeline and Increasing Diagnosis Rates | DelveInsight
PR Newswire —
The PSMA-targeted therapy market is expected to grow strongly, fueled by higher prostate cancer diagnosis rates, improved awareness of PSMA-based treatments, and an expanding clinical trial landscape of therapies such as Lantheus' Lu-177-PNT2002/[Lu-177]-PSMA-I&T/PNT-2002), Telix...